Literature DB >> 26718

Deposition of IgM and complement at the dermoepidermal junction in acute and chronic cutaneous graft-vs-host disease in man.

M S Tsoi, R Storb, E Jones, P L Weiden, H Shulman, R Witherspoon, K Atkinson, E D Thomas.   

Abstract

The presence of cutaneous immunoglobulin and complement was investigated in 88 patients with and without graft-vs-host disease (GVHD) after transplantation of bone marrow from HLA identical siblings for the treatment of acute leukemia or aplastic anemia. For comparison, skin biopsies from the patients obtained before transplantation, from 58 healthy individuals (mostly marrow donors) and from four syngeneic marrow recipients were studied. A direct immunfluorescent staining technique was used. Dermo-epidermal IgM deposits were found in 11% of healthy individuals and patients before grafting but were present in 86% of patients with chronic and 39% of patients with acute GVHD. Patients with allogeneic grafts who never had GVHD or who had recovered from it and patients with syngeneic grafts showed findings not different from those in healthy individuals. Findings similar to those with IgM, although less striking, were made for C3, i.e., patients who had chronic or acute GVHD had a high incidence and intensity of C3 deposits at the dermo-epidermal junction. This observation raises the possibility that humoral immunity is involved in the development of GVHD.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 26718

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  [Cutaneous graft-versus-host disease].

Authors:  S Karrer
Journal:  Hautarzt       Date:  2003-05       Impact factor: 0.751

2.  Complement C3a and C5a receptors promote GVHD by suppressing mitophagy in recipient dendritic cells.

Authors:  Hung Nguyen; Sandeepkumar Kuril; David Bastian; Jisun Kim; Mengmeng Zhang; Silvia G Vaena; Mohammed Dany; Min Dai; Jessica Lauren Heinrichs; Anusara Daenthanasanmak; Supinya Iamsawat; Steven Schutt; Jianing Fu; Yongxia Wu; David P Fairlie; Carl Atkinson; Besim Ogretmen; Stephen Tomlinson; Xue-Zhong Yu
Journal:  JCI Insight       Date:  2018-12-20

Review 3.  B cells in chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Bruce R Blazar; Corey Cutler; Jerome Ritz
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-12       Impact factor: 5.742

Review 4.  Immune complexes in human diseases: a review.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

5.  Fatal graft-versus-host reaction following granulocyte transfusions.

Authors:  W Schmidmeier; W Feil; W Gebhart; W Grisold; F Gschnait; W Hinterberger; P Höcker; K Jellinger; R Krepler; E Machacek
Journal:  Blut       Date:  1982-08

6.  The ultrastructure of the human epidermis in chronic graft-versus-host disease.

Authors:  B B Gallucci; H M Shulman; G E Sale; K G Lerner; L E Caldwell; E D Thomas
Journal:  Am J Pathol       Date:  1979-06       Impact factor: 4.307

Review 7.  Mesenchymal stromal cells: a new tool against graft-versus-host disease?

Authors:  Frédéric Baron; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2011-09-29       Impact factor: 5.742

8.  Pathology of the liver with bone marrow transplantation. Effects of busulfan, carmustine, acute graft-versus-host disease, and cytomegalovirus infection.

Authors:  W E Beschorner; J Pino; J K Boitnott; P J Tutschka; G W Santos
Journal:  Am J Pathol       Date:  1980-05       Impact factor: 4.307

9.  Complement component C3 mediates Th1/Th17 polarization in human T-cell activation and cutaneous GVHD.

Authors:  Q Ma; D Li; R Carreño; R Patenia; K Y Tsai; M Xydes-Smith; A M Alousi; R E Champlin; G E Sale; V Afshar-Kharghan
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

10.  Association of circulating immune complexes containing bovine proteins and graft-versus-host disease.

Authors:  C Cunningham-Rundles; R O'Reilly
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.